Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third-line irinotecan for recurrent or metastatic breast cancer in Northern China
ChiCTR1900021782Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in breast cancer, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: objective response rate. Planned start May 2019; status: not yet recruiting.
02
Drugs
irinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900021782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021782.